B+
Bull case
15%
Probability
Target price
$1.05
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
BBLG
Bone BiologicsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that the July financing removes an immediate liquidity cliff, the stated runway reaches Q2 2027, enrollment completes by year-end, and the 29-month rhNELL-1 shelf life supports smoother manufacturing and future clinical development [#8-K-2026-07-23].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
NB1 remains an early-stage clinical program; the checked sources do not provide current enrollment, efficacy, or safety data.
Momentum
82
Value
58
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.58 · Bull $1.05 · Bear $0.35Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.20
Why
Momentum82 · Δ7d -
Value58 · Δ7d 0.0
Sentiment62 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • NB1 remains an early-stage clinical program; the checked sources do not provide current enrollment, efficacy, or safety data.
- • No trustworthy post-earnings analyst estimate revisions, target changes, or market-reaction attribution were available in the packet.
- • The bear case remains stronger on current evidence: BBLG is an early-stage, loss-making biotech with substantial going-concern risk, ongoing financing needs, potential dilution, and no reported human efficacy or safety readout.
Catalyst clock
2026-08-14
Post-earnings liquidity checkpoint
Lead driver: Sentiment · See AI snapshot
Momentum
82
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.2
Sentiment
62
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 81.9 / Value 57.9 / Sentiment 61.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.58
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.82M
Beta
0.75
Shares Out
1.81M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.69
Rev YoY
-
EPS YoY
-67.6%
Gross Margin
-
Op Margin
-
Net Debt
-$5.33M
Current Ratio
8.67
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data